arrow
C

Clare Arnott

The George Institute for Global Health
H指数:31
被引数:5,687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: insights from the CREDENCE trial

卡格列净在CKD患者中不同联合用药负担下的疗效和安全性具有一致性:来自CREDENCE试验的见解

2026-09-040
OAAI
Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy on CKD progression

ZENITH高蛋白尿试验的设计和基线特征:评估zibotentan/dapagliflozin对CKD进展有效性的研究

2026-08-040
OAAI
DIVINE-pilot trial: a phase 2 multicentre, randomised pilot trial of pharmacotherapy and physical activity monitoring conducted in women with recent gestational diabetes and increased risk of type 2 diabetes recruited from tertiary referral hospitals in Australia

DIVINE-pilot试验:一项在澳大利亚三级转诊医院招募的、近期有妊娠糖尿病且2型糖尿病风险增加的女性中进行的、关于药物疗法和身体活动监测的二期多中心、随机试点试验。

2025-12-110
OA
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

瑞奈生命周期试验的原理与设计:评估达格列净对严重慢性肾病心血管肾脏结局的影响

2025-03-070
PRE
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy
2025-02-010
PRE
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

卡格列净在老年人中的心血管,肾脏和安全性结果: 来自CANVAS计划和cre登斯试验的联合分析

2025-01-090
PRE